IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	YU et al.	§	Docket No.: UTSD:0795
		§	
Serial No.:	TBA	§	Examiner:
		§	
Filing Date:	04/30/2001	§	Art Unit:
		§	
Title:	A CLASS OF 12MER PEPTIDES THAT	§	
	INHIBIT THE FUNCTION OF THE	§	
	MITOTIC CHECK POINT PROTEIN	§	
	MAD2	§	

Box Sequence Listing
Assistant Commissioner for Patents
Washington, D.C. 20231

SEQUENCE LISTING 37 CFR 1.821

Dear Sir:

In compliance with 37 CFR 1.821, Applicants submit the attached sequence listing and provide one enclosed 3.5 inch disk. The file is stored as Seq.txt.

I hereby state that the content of the paper and computer readable copies of the sequence listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

Applicant believes that there is no additional fee required to file this paper. If Applicant is in error, the Commissioner is hereby authorized to charge any required fees and/or credits by this paper and during the entire pendency of this application to Account No. 06-2375/10101381.

Respectfully submitted,

Melissa W. Acosta
Registration No. 45,872

Date: April 30, 2001

FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5407 (Telephone)
(713) 651-5246 (Facsimile)

SEQUENCE LISTING

<110> YU, HONGTAO
      TANG, ZHANYUN
      LUO, XUELIAN
      RIZO-REY, JOSE

<120> A CLASS OF 12MER PEPTIDES THAT INHIBIT THE FUNCTION OF THE MITOTIC CHECK
POINT PROTEIN MAD2

<130> UTSD:0795

<140> TBA
<141> 2001-04-30
<160> 20

<170> PatentIn version 3.0

<210> 1
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Synthetic Peptide

<220>
<221> misc_feature
<222> (6)..(6)
<223> X is any

<220>
<221> misc_feature
<222> (1)..(8)
<223> Synthetic Peptide

<400> 1

Gln Trp Tyr Lys Leu Xaa Pro Pro
1   5

<210> 2
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 2

Ser Trp Tyr Ser Tyr Pro Pro Pro Gln Arg Ala Val

Ser Trp Tyr Ser Tyr Pro Pro Pro Gln Arg Ala Val
1   5   10

<210>   3
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<221>   misc_feature
<222>   (1)..(12)
<223>   synthetic peptide

<400>   3

Asp Ala Arg Ile Ile Lys Leu Pro Val Pro Lys Pro
1   5   10

<210>   4
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<221>   misc_feature
<222>   (1)..(12)
<223>   synthetic peptide

<400>   4

Gln Trp Leu His Phe Ala Pro Pro Pro Pro Pro Lys
1   5   10

<210>   5
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<221>   misc_feature
<222>   (1)..(12)
<223>   synthetic peptide

<400>   5

Gln Trp Ile Thr Leu Ser Pro Pro Arg Ser Leu Thr
1   5   10

<210>   6
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>

<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 6

Ser Ala Asn Trp Thr Ile Trp Lys Pro Pro Thr Pro
1   5   10

<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 7

Asn Trp Tyr Ser Tyr Lys Met Pro Lys His Glu Ala
1   5   10

<210> 8
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 8

Gln Trp Leu Lys Phe Ser Pro Pro Met His Ala Ser
1   5   10

<210> 9
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(12)
<223> synthetic peptide

<400> 9

Gly Trp Val Arg Leu Gln Pro Pro Pro Leu Ile Gln
1   5   10

```
<210>   10
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<221>   misc_feature
<222>   (1)..(12)
<223>   synthetic peptide


<400>   10

Ala Trp Tyr Lys Leu Pro Lys Glu Ser Pro Leu Leu
1               5                   10

<210>   11
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<221>   misc_feature
<222>   (1)..(12)
<223>   synthetic peptide


<400>   11

Ser Trp Tyr His Thr Pro Ser Pro Leu Pro His Lys
1               5                   10

<210>   12
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<221>   misc_feature
<222>   (1)..(12)
<223>   synthetic peptide


<400>   12

Thr Trp Tyr Lys Leu Ser Asn Ser Pro Ile Tyr Gly
1               5                   10

<210>   13
<211>   14
<212>   PRT
<213>   Homo sapiens

<400>   13

Asp Val Glu Glu Ala Lys Ile Leu Arg Leu Ser Gly Lys Pro
```

<210> 14
<211> 15
<212> PRT
<213> Drosophila

<400> 14

Asp Ser Lys Gly Gly Arg Ile Leu Cys Tyr Gln Asn Lys Ala Pro
1   5   10   15

<210> 15
<211> 14
<212> PRT
<213> S. Cerevisiae

<400> 15

Asp Met Asn Lys Arg Ile Leu Gln Tyr Met Pro Glu Pro Pro
1   5   10

<210> 16
<211> 14
<212> PRT
<213> S. Pombe

<400> 16

Asp Leu Asn Thr Arg Val Leu Ala Phe Lys Leu Asp Ala Pro
1   5   10

<210> 17
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)..(1)
<223> X is any

<220>
<221> misc_feature
<222> (1)..(12)
<223> Synthetic Peptide

<220>
<221> misc_feature
<222> (6)..(7)
<223> X is any

<220>
<221> misc_feature

```
<222>  (9)..(12)
<223>  X is any


<400>  17

Xaa Trp Tyr Lys Leu Xaa Xaa Pro Xaa Xaa Xaa Xaa
1              5                   10


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<221>  misc_feature
<222>  (4)..(5)
<223>  X is any


<220>
<221>  misc_feature
<222>  (1)..(7)
<223>  Synthetic Peptide


<400>  18

Trp Tyr Lys Leu Xaa Xaa Pro
1              5


<210>  19
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<221>  misc_feature
<222>  (1)..(12)
<223>  Synthetic Peptide


<400>  19

Gly Trp Trp His Ile Pro Ser Pro Val Leu Arg Pro
1              5                   10


<210>  20
<211>  11
<212>  PRT
<213>  HIV-TAT PROTEIN

<400>  20

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1              5                   10
```